What does this research mean for the field?

The genes Hmgcs2 and Angptl4 are upregulated, while Slco1a1 is downregulated, across multiple experimental models of diabetic kidney disease, identifying them as novel gene factors implicated in the disease's progression. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

October 18, 2023BMC NephrologyOpen Access

Identifying key genes for diabetic kidney disease by bioinformatics analysis

View Full Paper

Ask AI

Bookmark

Why the study?

There are no reliable molecular targets for early diagnosis and effective treatment in the clinical management of diabetic kidney disease (DKD).

Population

Public transcriptomic datasets of alloxan-induced and streptozotocin-induced DKD models and validation in db/db DKD mice

Comparison

DKD models vs control animals

Design

Integrative bioinformatic analysis and animal model validation

Authors

YXYushan Xu LLLan Li PTPing Tang

Discussion

Member takes

Overview

Findings in rodent DKD models warrant human validation; leaves open biomarker or therapeutic potential.

Structured PICO

Population

Public transcriptomic datasets of alloxan-induced DKD model (GSE139317: 6 control, 9 DKD mice) and streptozotocin-induced DKD model (GSE131221: 5 control, 7 DKD rats), with validation in male C57BL/6 mice (n=5) and male db/db mice (n=5) at 15 weeks of age.

Intervention

Integrative bioinformatic analysis of differentially expressed genes (DEGs) and validation of key genes (Hmgcs2, Angptl4, and Slco1a1).

Comparator

Control animals (sham/wildtype).

Outcome

Identification of common differentially expressed genes (DEGs) and biological processes altered across DKD models.surrogate

Hmgcs2, Angptl4, and Slco1a1 are consistently altered in multiple experimental models of diabetic kidney disease, suggesting they may serve as novel biomarkers or therapeutic targets.

Limitations

Further verification of these genes in clinical samples is needed
Functional characterization is needed to confirm their implications in DKD

Cite This Study

Xu et al. (2023) studied this question.

synapsesocial.com/papers/6a19b420196cd56b09ea9802 https://doi.org/10.1186/s12882-023-03362-4

View Full Paper

Ask AI

Bookmark

October 18, 2023BMC NephrologyOpen Access

Identifying key genes for diabetic kidney disease by bioinformatics analysis

View Full Paper

Ask AI

Bookmark

Why the study?

There are no reliable molecular targets for early diagnosis and effective treatment in the clinical management of diabetic kidney disease (DKD).

Population

Public transcriptomic datasets of alloxan-induced and streptozotocin-induced DKD models and validation in db/db DKD mice

Comparison

DKD models vs control animals

Design

Integrative bioinformatic analysis and animal model validation

Authors

YXYushan Xu LLLan Li PTPing Tang

Discussion

Member takes

Overview

Findings in rodent DKD models warrant human validation; leaves open biomarker or therapeutic potential.

Structured PICO

Population

Intervention

Integrative bioinformatic analysis of differentially expressed genes (DEGs) and validation of key genes (Hmgcs2, Angptl4, and Slco1a1).

Comparator

Control animals (sham/wildtype).

Outcome

Identification of common differentially expressed genes (DEGs) and biological processes altered across DKD models.surrogate

Hmgcs2, Angptl4, and Slco1a1 are consistently altered in multiple experimental models of diabetic kidney disease, suggesting they may serve as novel biomarkers or therapeutic targets.

Limitations

Further verification of these genes in clinical samples is needed
Functional characterization is needed to confirm their implications in DKD

Cite This Study

Xu et al. (2023) studied this question.

synapsesocial.com/papers/6a19b420196cd56b09ea9802 https://doi.org/10.1186/s12882-023-03362-4

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark